Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Low dose of hydroxychloroquine is associated with reduced COVID-19 mortality: a multicenter study in China

He et al., Frontiers of Medicine, doi:10.1007/s11684-025-1123-9, NCT05615792
Mar 2025  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality, all patients 66% Improvement Relative Risk Mortality, low dose 74% Ventilation, all patients 25% Ventilation, low dose 27% ARDS, all patients 41% ARDS, low dose 49% AKI, all patients 31% AKI, low dose 30% Acute heart injury, all patie.. 38% Acute heart injury, low dose 39% HCQ for COVID-19  He et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 53,030 patients in China (December 2019 - August 2021) Lower mortality (p<0.0001) and ventilation (p=0.05) c19hcq.org He et al., Frontiers of Medicine, March 2025 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 422 studies, used in 58 countries.
No treatment is 100% effective. Protocols combine treatments.
5,400+ studies for 118 treatments. c19hcq.org
PSM retrospective 53,030 hospitalized patients in China showing low dose HCQ treatment associated with significantly lower all-cause mortality, mechanical ventilation, acute heart injury, and acute kidney injury, with benefits consistent across mild and critically ill patients.
Standard of Care (SOC) for COVID-19 in the study country, China, is average with moderate efficacy for approved treatments1.
risk of death, 66.0% lower, HR 0.34, p < 0.001, treatment 830, control 830, all patients, propensity score matching, Kaplan–Meier.
risk of death, 74.0% lower, HR 0.26, p < 0.001, treatment 800, control 800, low dose, propensity score matching, Kaplan–Meier.
risk of mechanical ventilation, 24.8% lower, HR 0.75, p = 0.05, treatment 841, control 52,189, inverted to make HR<1 favor treatment, all patients, Kaplan–Meier.
risk of mechanical ventilation, 27.0% lower, HR 0.73, p = 0.04, treatment 800, control 52,189, low dose, Kaplan–Meier.
ARDS, 40.8% lower, HR 0.59, p = 0.21, treatment 841, control 52,189, inverted to make HR<1 favor treatment, all patients, Kaplan–Meier.
ARDS, 49.0% lower, HR 0.51, p = 0.13, treatment 800, control 52,189, low dose, Kaplan–Meier.
AKI, 31.0% lower, HR 0.69, p = 0.005, treatment 841, control 52,189, inverted to make HR<1 favor treatment, all patients, Kaplan–Meier.
AKI, 30.0% lower, HR 0.70, p = 0.008, treatment 800, control 52,189, low dose, Kaplan–Meier.
acute heart injury, 37.9% lower, HR 0.62, p = 0.03, treatment 841, control 52,189, inverted to make HR<1 favor treatment, all patients, Kaplan–Meier.
acute heart injury, 39.0% lower, HR 0.61, p = 0.02, treatment 800, control 52,189, low dose, Kaplan–Meier.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
He et al., 4 Mar 2025, retrospective, China, peer-reviewed, 9 authors, study period 29 December, 2019 - 31 August, 2021, trial NCT05615792 (history). Contact: dwwang@tjh.tjmu.edu.cn.
This PaperHCQAll
Abstract: Front. Med. https://doi.org/10.1007/s11684-025-1123-9 LETTER TO FRONTIERS OF MEDICINE Low dose of hydroxychloroquine is associated with reduced COVID-19 mortality: a multicenter study in China ✉)1 Wu He1,*, Ke Xu1,*, Yongcui Yan1, Gen Li1, Bo Yu1, Junfang Wu1, Kaineng Zhong2, Da Zhou2, Dao Wen Wang ( 1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China; 2Health Commission of Hubei Province, Wuhan 430079, China © Higher Education Press 2025 Dear Editor, Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has widely spread worldwide, and we have been fighting against coronavirus disease 2019 (COVID-19) for more than 4 years [1]. According to the statistics of the World Health Organization (WHO), more than 775 million individuals have incurred COVID-19, and 7 million deaths have been recorded. The COVID-19 outbreak has become a devastating global health crisis, and the challenges faced by humanity due to this disease are continuing [2]. In the past 4 years, an old antimalarial drug, hydroxychloroquine (HCQ), has been evaluated by doctors and scientists [3]. Its effects on the immune system have been fully confirmed, including inhibition of Toll-like receptor signals and lymphocyte receptors; interference with lysosomal acidification, antigen presentation, and DNA binding and stabilization; and reduction of proinflammatory cytokines produced by macrophages (especially IL-1, IL-6, and TNF-α) [4]. In vitro experiment of HCQ showed its efficacy in inhibiting novel coronaviruses and its greater effectiveness than chloroquine [5]. Our previous clinical results also supported that HCQ has good therapeutic effects on patients with COVID-19 [6]. An observational study revealed that the use of HCQ was associated with a reduced hospitalization rate among patients with COVID19 [7]. Nevertheless, some studies reported neutral or negative findings on the clinical results and meta-analysis of patients with COVID-19 treated with HCQ [8], leading to doubts and restrictions on the clinical use of HCQ on patients with COVID-19 to a certain extent. We conducted a multicenter retrospective study of Received August 5, 2024; accepted December 16, 2024 Correspondence: Dao Wen Wang, dwwang@tjh.tjmu.edu.cn *These authors contributed equally to this work. 53 030 patients with COVID-19 (discharged or deceased) in 138 hospitals in Hubei Province to clarify the effects of different HCQ doses on the mortality of patients with COVID-19 (Trial registration: NCT05615792). Under China and WHO interim guidance, all the patients diagnosed with COVID-19 between Dec 29, 2019 (i.e., when the first patients were admitted) and Aug 31, 2021 were screened, and those who had died or were discharged were included in this study. The patients were divided into HCQ group and non-HCQ group according to whether or not they were administered with HCQ. A 1:1 propensity score matching (PSM) analysis was used to balance the confounding factors between HCQ group and non-HCQ group. The HCQ group consisted of patients with COVID-19 who continuously received HCQ for more than 3 days. According to the dosage, the HCQ group was subdivided into high-dose (≥ 400 mg/d) and low-dose (< 400 mg/d) groups. This study included 68 128 patients with COVID-19 from 138 hospitals..
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit